To address the need for novel alternatives to antibiotics, we attempted to sensitize gram-negative bacilli to innate antibacterial protagonists. We report a lipopeptide-like sequence (C 10 OOc 12 O) that inflicted outer membrane damage at a low micromolar range, whereas measurable bacterial growth inhibition in broth medium required >10-fold higher concentrations. In serum, however, C 10 OOc 12 O induced antibacterial activity in a manner suppressible by anticomplement antibodies or heat treatment and acted synergistically with exogenous lysozyme in broth and serum media. Upon subcutaneous administration, C 10 OOc 12 O exhibited high circulating levels that correlated with significant therapeutic efficacies, using either the mouse peritonitis-sepsis model or the thigh infection model. These findings are consistent with the view that, by damaging the outer membrane, C 10 OOc 12 O was able to enhance gram-negative bacilli susceptibility to antibacterial components of the immune humoral arm. Such lipopeptides may therefore be useful in fighting gram-negative bacilli threats through sensitization to endogenous and/or exogenous antibacterial proteins such as lysozyme and complements.
Among the solutions proposed to overcome the current antibiotic deadlock [1] [2] [3] , membrane-active compounds attract a renewed attention for their potential to affect a variety of critical bacterial processes [4, 5] . Because membrane-active compounds are able to target multiple vital bacterial functions simultaneously [6] , they may overcome infections while avoiding many of the known resistance mechanisms. Unlike hydrophobic membrane-active compounds (eg, dermaseptins [7] ) that instigate drastic membrane disruption that, ultimately, may kill bacteria, borderline-hydrophobic membrane-active compounds involved in superficial membrane interactions [6] tend to cause damage that, while repairable [8, 9] , confers a high metabolic cost to bacteria. For instance, the ordered packing of the membrane constituents can be distorted by steric hindrance of bulky membrane-active compounds to a level whereby transient proton leakage occurs, thereby temporarily affecting the transmembrane potential, which is required for vital bioenergetics [10] and transport functions [11] . Although bacteria may be more likely to acquire resistance to a bacteriostatic rather than a bactericidal antibiotic, experimental evidence indicates that, in the presence of a borderline-hydrophobic membraneactive lipopeptide, bacteria were less likely to develop resistance to conventional antibiotics [12] .
While this scenario was proposed to sensitize gram-negative bacteria to efflux substrate antibiotics [13] , a recent follow-on study [14] suggested that similar membrane-active compound interactions with the outer membrane might sensitize gram-negative bacteria to low permeability antibiotics [15] . Thus, a lipopeptide-like short sequence (C 10 KKc 12 K) was generated following structure-activity relationship studies of a synthetic library of cationic membrane-active compounds, termed "oligomers of acylated lysyls" (OAKs) [16, 17] . This lipopeptide was particularly interesting since, despite its inefficiency in inhibiting gram-negative bacterial proliferation (a consequence of its efflux by RND pumps), C 10 KKc 12 K has permeabilized their outer membrane to the hydrophobic antibiotic rifampin. Moreover, combining C 10 KKc 12 K and rifampin in systemic treatment of infected mice had superior efficacy over individual administration of the drugs, thereby attributing the enhanced in vivo performance of C 10 KKc 12 K to its increased bioavailability and capacity for outer membrane permeabilization. Here, to verify the underlying expectancies, we challenged this lipopeptide approach by asking whether the postulated OAK-mediated in vivo outer membrane damage [14] could allow bacterial sensitization to innate factors associated with the blood antibacterial properties [18, 19] . Some of these factors, such as lysozyme, that damage bacterial cell walls within lysosomal phagocytes [20] and in the serum-soluble form [19] are clearly underexploited for therapeutic purposes.
[ATCC]; Manassas, VA), E. coli strain ATCC 25922, Klebsiella pneumoniae clinical isolate 1287, K. pneumoniae carbapenemase 2-producing strain, Salmonella enterica serovar Choleraesuis (ATCC 7308), S. enterica serovar Typhimurium (ATCC 14028), and Pseudomonas aeruginosa clinical isolates 11662 and 11816. The following gram-positive species was investigated: methicillin-resistant Staphylococcus aureus clinical isolate USA300 10017 (a gift from Dr Gili RegevYochay, Infectious Disease Unit, Sheba Medical Center, Israel).
Peptide synthesis was performed in-house by the solid-phase method [21] , as described elsewhere [16] . Organization in aqueous solution was assessed by light-scattering measurements in phosphate buffered saline (PBS; 10 mM Na 2 HPO 4 , 150 mM NaCl, pH = 7.0) as detailed previously [14] . Hemolytic assays were performed as described elsewhere [14] , using fresh mouse red blood cells.
Minimal inhibitory concentrations (MICs) were determined as previously described [14] . Inhibition was determined by optical density measurements (at 620 nm) after incubation overnight at 37°C. Data were obtained from ≥2 independent experiments performed in duplicate.
Membrane permeabilization was assessed using E. coli ML-35p as described elsewhere [22] , to monitor the ability of OACs to perturb the outer and/or cytoplasmic membranes. Reported data were obtained from ≥2 independent experiments performed in duplicate.
Serum survival assays were performed using fresh serum from normal mice or human serum from the Israel Blood Bank; samples were pooled and stored in aliquots at -80°C until use. Time-dependent killing was determined in a final volume of 125 µL consisting of 112.5 µL of serum containing either C 10 OOc 12 O, egg white lysozyme (Amresco), lactoferrin (Vivinal lactoferrin FD; DMV International, Delhi, NY), anti-murine C5/C5a antibody (25 µg/mL; ab194637; Abcam), or their combination, as specified. These solutions were supplemented with 12.5 µL of bacteria suspended in PBS at the desired concentration. After the specified time points of exposure, cultures were subjected to serial 10-fold dilutions in saline (0.85% NaCl) and plated for bacterial enumeration after incubation at 37°C for an additional 24 hours. In heat-treated experiments, sera were incubated at 56°C for 30 minutes for protein inactivation. Data were obtained from 3 independent experiments.
In vivo studies described below were performed using male ICR mice (mean weight [± SD], 23 ± 2 g) obtained from Envigo Laboratories (Rehovot, Israel).
Ethics Statement
All animal experiments were reviewed and approved by the Technion Animal Care and Use Committee. Procedures and the care and handling of animals were performed according to the Guide for the Care and Use of Laboratory Animals, published by National Research Council of the United States and adopted by the Israel Ministry of Health. All experiments were performed according to approved institutional animal care and use committee protocols (IL-041-03-14 and IL-076-07-11).
Toxicity
The maximum tolerated dose was determined after a single-dose subcutaneous administration of oligomers of acylated cations (OACs; C 10 KKc 12 K, C 10 OOc 12 O, and C 10 RRc 12 R), using 8, 8, and 2 mice, respectively. Animals were inspected for adverse effects for 6 hours after injection. Mortality was monitored for 7 days thereafter.
Pharmacokinetic studies were performed as described elsewhere [14] .
A mouse peritonitis-sepsis model was created as previously described [14] . Infection was obtained after intraperitoneal injection of bacteria from a logarithmic-phase culture. Infected mice were treated subcutaneously. The doses were selected to allow comparison with the reference OAC and to remain below the maximum tolerated dose after double-dose administration. Typically, treating this infection model by using ciprofloxacin or imipenem yields a survival frequency of 80%-100% [16, 23] . Statistical analyses were performed using a paired t test with an α level of 0.05.
Mouse Thigh Infection Model
Normal ICR mice were inoculated intramuscularly and treated subcutaneously 1 hour thereafter with C 10 OOc 12 O or polymyxin B (PMB; Sigma-Aldrich) as described elsewhere [13] . P values were calculated using a 1-tailed t test (assuming unequal variance). A P value of < .05 is considered statistically significant.
Enzyme-linked immunosorbent assays were performed using blood samples collected from mice 24 hours after infection and centrifuged (at 1000×g for 5 minutes). Murine tumor necrosis factor α levels were determined in accordance with the manufacturer instructions (PeproTech).
RESULTS

An OAC Lacking Antibiotic Activity Damages the Outer Membrane and Exhibits Higher Blood Levels
Initial work aimed to identify an analog with improved bioavailability as compared to that for C 10 KKc 12 K. In particular, we sought a candidate that maintains membrane-active properties while being devoid of antibiotic activity per se (ie, unable to kill bacteria on its own but able to induce killing via a third party); such an OAK would expand the sensitivity spectrum to include low permeability antimicrobials, yet it would lack antibiotic activity, which might give it mechanistic advantages (eg, in avoiding ambiguity as to "who is doing what" among the paired reagents) during combination experiments. Depicted in Figure 1A is the structure of the reference sequence and 2 substitution analogs that resulted from the study. Because they were designed to test the consequences of replacing the lysine residues with different cationic residues, the OAK analogs will be referred to herein as OACs. Figure 1B summarizes relevant biophysical attributes of the analogous OACs. The data indicate that, while C 10 OOc 12 O was less hydrophobic than C 10 KKc 12 K, it exhibited similar features in terms of organization in solution and inactivity on bacteria (the minimal bactericidal concentration was >50 μM for E. coli and K. pneumoniae) or on erythrocytes (the concentration required to induce 50% hemolysis was extremely high [ie, 50% lethal concentration, >100 μM]). In contrast, C 10 RRc 12 R displayed a higher hydrophobicity, coupled with some hemolytic and antibacterial capacities. Combined, these data provide evidence for the consistent inefficiency of C 10 OOc 12 O in significantly affecting growth of gram-negative bacteria.
Additional support for this view was obtained by comparing the OACs' susceptibility to damage gram-negative bacteria membranes, using the E. coli mutant ML-35p [22] . Widely described in the literature, the mutant was considered here as representative of all gram-negative bacteria, rather than a specific species. This mutant is constitutive for cytoplasmic β-galactosidase, lacks lactose permease, and expresses a plasmid-encoded periplasmic β-lactamase. Two chromogenic reporter molecules (nitrocefin and 2-nitrophenyl β-d-galactopyranoside, respectively, absorbing at 486 and 420 nm) are used to monitor permeabilization of the outer membrane and/ or cytoplasmic membrane in a single assay. Figure 2A indicates that C 10 OOc 12 O and C 10 KKc 12 K were similarly potent in inducing outer membrane permeabilization and similarly unable to permeabilize the cytoplasmic membrane at least up to approximately 10 µM ( Figure 2B ), whereas C 10 RRc 12 R exhibited somewhat higher tendency for cytoplasmic membrane damaging. Figure 2C compares the plasma concentrations of these analogs, as determined by quantitative liquid chromatography-mass spectrometry following subcutaneous administration (dose, 12.5 mg/kg body weight each to allow comparison with the previously tested analog, C 10 KKc 12 K) to ICR mice. While the lipopeptides achieved circulating levels of magnitudes comparable to those of classical antibiotics [24] , their concentrations correlated with their hydrophobicity, predicting a comparatively low bioavailability for C 10 RRc 12 R (whose maximal extractable levels were <3 µM). Similarly, the data predicted a relatively higher bioavailability of C 10 OOc 12 O, whose extractable levels consistently were >5 µM throughout at least 2 hours after administration. This value will bare importance in subsequent studies (such as those summarized in Figure 3B ). Subcutaneous administration of the highest tested dose (20 mg/kg) was well tolerated, as no adverse effects were observed for any of the analogous OACs (ie, the maximal tolerated dose is estimated to be >20 mg/kg body weight). Collectively, these findings support the view that, while C 10 OOc 12 O is as efficient as the reference OAC in altering outer membrane permeability, it is at least as inefficient in affecting gram-negative bacteria growth but promises improved pharmacokinetics. This sequence was deemed to have the highest potential to address the study's aim and was therefore selected to undergo further characterization.
C 10 OOc 12 O Enhances Serum Antibacterial Properties
Reportedly, the bactericidal activity of polymyxins against E. coli, as observed in serum at sub-MIC conditions, was mediated by complement proteins [25, 26] . This prompted us to explore the antibacterial properties of C 10 OOc 12 O in serum. Our findings indicate that, in mouse serum, C 10 OOc 12 O effectively inhibited growth of serum-resistant gram-negative bacteria (74% and 48% inhibition of E. coli and K. pneumoniae, respectively), whereas inhibition diminished when serum was supplemented with an antibodydirected against the complements C5/C5a ( Figure 3A ) or when saturated with high inocula (data not shown). To validate this activity, we also determined bacterial survival in mouse serum obtained 1 hour after subcutaneous administration of C 10 OOc 12 O (the serum concentration was assumed to be >5 μM, according to Figure 2C ). The subsequent inoculation and culture were as described in Figure 3A , while additionally, a duplicated sample was subjected to heat treatment. As shown in Figure 3B , the OAC-containing serum also exhibited growth inhibitory activity (80% inhibition; P = .05). The fact that this inhibition was antagonized by heat treatment substantiated the fold-dependent proteinaceous nature of the antibacterial factor, be it complement or another polypeptide(s). This experiment, therefore, joins the previous finding in suggesting that C 10 OOc 12 O might have the capacity to recruit some component(s) of the immune system, as host defense peptides (HDPs) might do [27] . Since various proteins other than antibodies were implicated in observable serum antibacterial properties [28] , we next explored the possible role of nonantibody proteins by exposing bacteria to C 10 OOc 12 O in the presence of lysozyme [29, 30] , which is known to damage bacterial cell walls by catalyzing peptidoglycan degradation. It is less effective on gram-negative bacteria because their peptidoglycan is less accessible, owing to the outer membrane barrier. Our strategy, therefore, aimed to exploit this fact, predicting that lysozyme activity will increase if C 10 OOc 12 O increases the outer membrane permeability (as per Figure 2A) . Results of the bacterial survival under roughly similar conditions (ie, after 3 h incubation in 80% serum) when the serum was obtained 1 h after subcutaneous OAC administration as described in Figure 2c followed by E. coli 25922 inoculation and culture as in panel a. The plot also shows a duplicated sample subjected to heat-treatment (HT). Error bars represent standard deviations from the mean. following studies, performed in broth medium and in serum, support this notion.
Checkerboard-type experiments exposing bacteria to lysozyme and/or to C 10 OOc 12 O in growth medium revealed a dose-dependent synergistic growth inhibition of E. coli and K. pneumoniae in the presence of both drugs combined but not individually ( Figure 4A and 4B) . Synergism persisted in serum ( Figure 4C and 4D) , indicating that, under conditions where lysozyme or C 10 OOc 12 O were virtually inactive, the lysozyme-supplemented serum became bactericidal in presence of C 10 OOc 12 O.
This synergism was much more potent in serum, as evident from E. coli counts ( Figure 4A and 4C ). While the difference in growth was negligible between medium and serum (from 4 to 9.8 log colony-forming units (CFU)/mL and from 4 to 9.7 log CFU/mL, respectively), comparison of the samples treated with 10 μM C 10 OOc 12 O plus 18 μM lysozyme to those that were untreated revealed a much greater difference in growth (from 4 to 9 log CFU/mL and from 4 to 1.7 log CFU/mL, respectively). This large difference reflects the fact that additional antibacterial factors (including endogenous lysozyme and complement) were implicated in serum. Albeit, no significant sensitization was observed with lactoferrin, another host defense antimicrobial protein ( Figure 4C and 4D) , possibly hinting to a limitation imposed by size, since lactoferrin is >5-fold larger than lysozyme. Synergism between serum components and PMB was previously observed in gram-negative bacteria both in growth medium [31] and serum [25] .
The mouse serum antibacterial properties in the presence of C 10 OOc 12 O were readily replicated in human serum ( Figure 5 and Supplementary Figure 1) . In this respect, however, PMB nonapeptide exhibited antibacterial activity in human but not mouse serum (perhaps because diluted serum was used) [32] . Also noteworthy is the fact that supplementation of human serum with lysozyme or lactoferrin resulted in similar outcomes as in mouse serum in terms of the synergy between C 10 OOc 12 O and lysozyme for both E. coli ( Figure 5B ) and K. pneumoniae (Supplementary Figure 1B) . However, unlike in culture medium, where C 10 OOc 12 O was clearly devoid of antibacterial activity ( Figure 1B and Supplementary Figure 2) , C 10 OOc 12 Otreated serum exhibited significant growth inhibition in absence of exogenous lysozyme, whereas a potent bactericidal effect was observed in its presence. Thus, given the significant endogenous levels of complement [33] and lysozymes [34] in mammalian sera, our findings support the possible implication of these compounds (and, conceivably, other serum-soluble antibacterial compounds) in mediating the eventual induction of in vivo antibacterial activity of bioavailable compounds that have the capacity to damage the outer membrane, despite being devoid of antibacterial activity themselves. Data summarized in Figures 6 and 7 support this view.
OAC-Mediated Protection From Sepsis
Under the experimental settings previously used [14] , C 10 OOc 12 O revealed a potent capacity to counteract the induced disease course. Figure 6A shows that, after administration of a single dose, C 10 OOc 12 O protected 40% of E. coliinfected mice from developing fatal sepsis; infection with this highly virulent pathogen resulted in the death of 100% of vehicle-treated mice. Moreover, multidose experiments revealed that a lower dose administrated twice further increased the survival rate to 70%. A comparable outcome was obtained with another species representing medically relevant gram-negative bacteria, K. pneumoniae, with survival frequencies of 60% and 90% after administration of similar single and double doses, respectively, to mice, thereby reinforcing the postulated efficacy of C 10 OOc 12 O monotherapy against gram-negative bacteria and suggesting its potentially improvable effectiveness via optimization of the treatment regimen.
This efficacy level is remarkable since, previously, under identical conditions, systemic treatment of K. pneumoniaeinfected mice with C 10 KKc 12 K resulted in weak efficacies (survival frequency, 0%-20%) [14] , whereas here, treatment using C 10 OOc 12 O achieved survival frequencies of up to 90% among animals. To our knowledge, such systemic efficacy against gram-negative bacteria, exerted by a peptide devoid of antibiotic activity, has hitherto been unreported. The closest case reports involved the use of a mouse model in which E. coli infection and peptide treatment were both performed intraperitoneally, with significant reduction in growth achieved despite the peptide's inefficient antibiotic activity in vitro [35] . However, since peptide administration was performed 4 hours before infection, this implies that the peptide fraction interacting with bacteria was excessively low. Consequently, this peptide must act by a different mechanism (ie, by activation of cellular immunity), as suggested by the authors.
Evidence for direct interaction of C 10 OOc 12 O with the test bacteria in vivo was obtained using an analogous experiment, which assessed in vivo efficacy under conditions where the OAC-bacteria interaction is unquestioned. First, bacteria were exposed to C 10 OOc 12 O (5 μM for 15 minutes) and then inoculated onto neutropenic mice. As shown in Figure 6B , mortality induced by the pretreated bacteria was significantly prevented (animal survival increased from 10% to 40% and from 35% to 70% for infections by E. coli or K. pneumoniae, respectively). These findings support a cause-and-effect relationship between direct OAC interaction with bacteria and survival of infected mice ( Figure 6A ). Supplementary Figure 2 shows the growth kinetics of strains used in vivo, as monitored in vitro. The practically identical curves obtained in the presence and absence of C 10 OOc 12 O (P = .4 and .9, respectively) join the data presented in Figure 1B in confirming that the observed in vivo efficacies are unlikely to stem from the direct antibiotic activity of C 10 OOc 12 O since its blood concentrations are unlikely to approach growth-inhibitory levels (observable at >50 µM in culture medium). These findings therefore indicate that some antibacterial cofactor(s) is required to explain the OAC-mediated efficacy. Thus, combined with the data from the previous sections, the findings suggest that, by minimizing nonspecific interactions with multiple amphipathic/anionic tissue constituents, C 10 OOc 12 O has achieved the high circulating levels necessary to attain the inoculated pathogens and neutralize their disease inducing capacity.
Next, we investigated the possibility that C 10 OOc 12 O, an HDP mimic, can affect bacterial viability in mice by recruiting cellular immunity component(s), since various HDPs [36] and HDP-like compounds [27] were reported to exert various immunomodulatory activities. For this purpose, we used the thigh infection model, created using nonlethal inoculums for inducing intramuscular infections in normal (nonneutropenic) mice, and assessed the viability of inoculated bacteria after systemic treatment. C 10 OOc 12 O and PMB reduced the number of inoculated E. coli by 80% and 64%, respectively ( Figure 7A ), under conditions in which the initial inoculum in vehicle-treated control mice was nearly unchanged, reflecting the phagocytes' ability to limit proliferation of the inoculated bacteria. Under the same conditions, C 10 OOc 12 O also significantly inhibited proliferation of K. pneumoniae ( Figure 7C ).
PMB, a toxic last resort antibiotic [37] used here as a reference antibiotic because of its potent bactericidal activity against gram-negative bacteria [38] , was nearly as efficacious as C 10 OOc 12 O, although its in vivo activity might stem from a direct bactericidal mechanism [39] , immune sensitization, or a combined effect. Nonetheless, the fact that a bactericidal antibiotic did not reduce the CFU count more than C 10 OOc 12 O (which is devoid of antibiotic activity) raises the possibility that, in vivo, PMB is not necessarily bactericidal but might merely facilitate the antibacterial activity of serum components, as proposed for C 10 OOc 12 O. Extending the comparison to toxicity issues, noteworthy is the finding that subcutaneous administration of C 10 OOc 12 O did not result in any visible adverse effect (eg, signs of discomfort or stress) at the highest tested dose (ie, 20 mg/kg body weight), a dose at which PMB was reported to cause zero mortality, as well [40] .
Also, under the tested conditions, both compounds failed to produce a significant change in the systemic levels of tumor necrosis factor α (a major immune marker orchestrating the host innate responses to infection [41] ), as measured prior to and 24 hours after infection with E. coli ( Figure 7B) or Klebsiella [42] , even at 100-fold higher inoculum, thereby arguing against the involvement of activated proinflammatory pathways in the observed outcome. The fact that in vivo efficacies of C 10 OOc 12 O ( Figure 6 ) were observed under neutropenic conditions also argues against a critical role played by the host immune cellular arm, although other cell types might have fulfilled the leukocytes' role [43, 44] . Thus, the involvement of cellular immunity remains unsettled and requires additional studies. Regardless, the fact that C 10 OOc 12 O can similarly affect the CFU counts of both E. coli and K. pneumoniae but not S. aureus (Figure 7D ), supports the notion that the effect of C 10 OOc 12 O is directed against gram-negative species whose lipopolysaccharide may leach (because of outer membrane damage, as evidenced in Figure 2A ) and stimulate the local recruitment of yet undetermined innate immune factors.
DISCUSSION
The combined data provide novel evidence for the ability of a new, linear, short lipopeptide to control gram-negative bacteria infections systemically, while being devoid of antibiotic activity. The molecular basis for this effect is yet ill understood, but our findings suggest a plausible role for C 10 OOc 12 O as a membrane-active compound that renders bacteria vulnerable to humoral antibacterial factors. The circulating concentration of C 10 OOc 12 O required for this activity (ie, <10 µM) is reasonably attainable at nontoxic doses. Other lipopeptides, such as polymyxins [26] , might achieve a similar biomedical potential [45] , although the design of OACs may present advantages, as demonstrated in terms of synergistic efficacy [14] or their molecular simplicity.
Beyond the specific attributes of C 10 OOc 12 O, this study also suggests that, to provide effective protection against gramnegative bacteria in vivo, HDPs are not required to exert bactericidal activity. Both experimental data and logic support this view. Indeed, the canonical mammalian HDPs-defensins or cathelicidins-often exhibit rather high MICs and/or bactericidal values [46, 47] . These characteristics argue against their touted critical role in direct bactericidal activity, suggesting that they need only to overcome the outer membrane permeability barrier to expedite the action of bactericidal humoral and/or cellular immune components. Such a mechanism may be advantageous as its milder action reduces the risk for complications associated with endotoxins released by bactericidal compounds [9, 48] , thereby promoting a smoother restoration of homeostasis. In this sense, borderline-hydrophobic membrane-active compounds may present an advantage over outright-hydrophobic counterparts.
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